A PATIENT-CENTERED APPROACH TO THE MANAGEMENT OF DEPRESSION
|
|
- August Pierce
- 6 years ago
- Views:
Transcription
1 Education Partner A PATIENT-CENTERED APPROACH TO THE MANAGEMENT OF DEPRESSION November 15, 212 Boston, Massachusetts
2 Session 3: A Patient-Centered Approach to the Management of Depression: Achieving and Maintaining Remission in the Primary Care Setting Learning Objectives 1. Develop strategies for effectively screening patients for depression within the boundaries of the primary care office visit. 2. Evaluate measurement-based care, specifically the APA guidelines, and strategies to address failure of initial antidepressant therapy. 3. Apply clinical data and guideline recommendations in creating an individualized, appropriate, and effective treatment plan. Sloan Manning, MD Adjunct Associate Professor University of North Carolina Chapel Hill, North Carolina Co-Director, Mood Disorders Clinic Moses Cone Family Practice Residency Greensboro, North Carolina Dr Manning is adjunct associate professor in the department of family medicine at the University of North Carolina at Chapel Hill. He also serves as co-director of the Mood Disorders Clinic at the Moses Cone Family Practice Residency in Greensboro, North Carolina. He earned his MD from the University of Mississippi Medical Center and completed his residency in family practice at Baptist Memorial Hospital in Gadsden, Alabama. He is board certified by the American Board of Family Practice, and is a member of both the American Academy of Family Physicians and the North Carolina Academy of Family Physicians. Dr Manning is the founding editor of The Primary Care Companion to The Journal of Clinical Psychiatry, and has authored or coauthored more than 5 letters, articles, and editorials in a variety of journals, including Archives of Family Medicine, Bipolar Disorders, Comprehensive Psychiatry, Journal of Affective Disorders, Journal of Clinical Psychiatry, North American Clinics of Psychiatry, and The Journal of Family Practice. He is also a reviewer for the Journal of Affective Disorders. His research interests include integrated somatic/mental health care systems in primary care, physician education in primary care psychiatry, and disorders of the bipolar spectrum, including their temperamental underpinnings and pharmacologic management. He was a member of the national coordinating council for the STABLE project, researching performance measures and quality improvement initiatives for bipolar treatment. Roger S. McIntyre, MD, FRCPC Professor of Psychiatry and Pharmacology Head, Mood Disorders Psychopharmacology Unit Toronto, Ontario, Canada Dr McIntyre is currently professor of psychiatry and pharmacology at the University of Toronto and head of the mood disorders psychopharmacology unit at the University Health Network, Toronto, Canada. He is involved in multiple research endeavors that primarily aim to characterize the association between mood disorders and medical comorbidity. This research involves elucidating metabolic adverse events associated with the use of psychotropic medications, the impact of medical comorbidity on the course of mood disorders, and the effect of glucose homeostasis on neurocognition. Dr McIntyre is a contributor to the Canadian Psychiatric Association (CPA) guidelines for the treatment of depressive disorders and the Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of bipolar disorder. He has published extensively in leading peer-reviewed journals and textbooks. Dr McIntyre is also a reviewer for many journals including the American Journal of Psychiatry, Biological Psychiatry, Journal of Clinical Psychiatry, and The New England Journal of Medicine, and serves as a grant reviewer for the National Institute of Mental Health. He completed his MD at Dalhousie University and did his psychiatry residency training and fellowship in psychiatric pharmacology at the University of Toronto. Session 3
3 Faculty Financial Disclosure Statements The presenting faculty reports the following: Dr Manning has disclosed that he is a consultant for AstraZeneca, Eli Lilly, Lundbeck, PamLab LLC, and Takeda. He is also a member of the speakers bureaus for AstraZeneca and Eli Lilly. Dr McIntyre has disclosed that he is a consultant for AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Janssen-Ortho, Eli Lilly, Lundbeck, Merck, Organon, Pfizer, and Shire. He is a member of the speakers bureaus for AstraZeneca, Biovail, Bristol-Myers Squibb, Eli Lilly, Merck, and Pfizer and receives grant/research support from AstraZeneca, Eli Lilly, Janssen, Lundbeck, Pfizer, and Shire. Education Partner Financial Disclosure Statement The content collaborators at Creative Educational Concepts report the following: Joan B. Fowler, PharmD, BCPP-Vice-President, has no financial relationships to disclose. Nathan Hamilton, PharmD-Clinical Support, has no financial relationships to disclose. Ashley C. Lilly, MHA-Account Director, has no financial relationships to disclose. Suggested Reading List Gaynes BN, Rush AJ, Trivedi MH, et al. The STAR*D study: treating depression in the real world. Cleve Clin J Med. 28;75(1): Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. 29;117(Suppl 1):S26-S43. McIntyre RS. When should you move beyond first-line therapy for depression? J Clin Psychiatry. 2;71(Suppl 1):16-2. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebocontrolled randomized trials. Am J Psychiatry. 29;166(9): Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry. 29;7(Suppl 6): Perahia DG, Quail D, Desaiah D, et al. Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques. J Clin Psychiatry. 28;69(1):95-5. Szegedi A, Jansen W, van Willigenburg AP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 29;7(3): Session 3
4 Session 3 :45 AM - 12: PM A Patient-Centered Approach to the Management of Depression: Achieving and Maintaining Remission in the Primary Care Setting Speakers: Sloan Manning, MD Roger S. McIntyre, MD, FRCPC Presenter Disclosure Information The following relationships exist related to this presentation: Dr Manning has disclosed that he is a consultant for AstraZeneca, Eli Lilly, Lundbeck, PamLab LLC, and Takeda. He is also a member of the speakers bureaus for AstraZeneca and Eli Lilly. Dr McIntyre has disclosed that he is a consultant for AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Janssen-Ortho, Eli Lilly, Lundbeck, Merck, Organon, Pfizer, and Shire. He is a member of the speakers bureaus for AstraZeneca, Biovail, Bristol-Myers Squibb, Eli Lilly, Merck, and Pfizer and receives grant/research support from AstraZeneca, Eli Lilly, Janssen, Lundbeck, Pfizer, and Shire. Off-Label/Investigational Discussion: In accordance with pmicme policy, faculty have been asked to disclose discussion of unlabeled or unapproved use(s) of drugs or devices during the course of their presentations. Drugs Referenced in Symposium A Patient Centered Approach to the Management of Depression: Achieving and Maintaining Remission in the Primary Care Setting Aripiprazole Bupropion Buspirone Citalopram Duloxetine Escitalopram Lithium Milnacipran Mirtazapine Nortriptyline Olanzapine Quetiapine Risperidone Sertraline Triiodothyronine Venlafaxine Please indicate the approximate number of patients that you see each week with depression 1. None 2. 1 to to to to to to Which of the following is a realistic goal for a patient undergoing treatment for MDD? 1. 75% reduction in depression score % reduction in depression score % reduction in depression score 4. <25% reduction in depression score 1
5 Which of the following is not an appropriate firstline switch in a patient who has failed an SSRI? 1. Escitalopram 2. Duloxetine 3. Buspirone 4. Mirtazapine 5. Bupropion Which of the following can most reliably be performed in the confines of the modern 15 minute office visit? 1. 9 item Patient Health Questionnaire item Hamilton Depression Rating Scale 3. Montgomery Asberg Depression Rating Scale 4. Quick Inventory of Depressive Symptomatology Self Report Which of the following statements is true regarding antidepressant response at 2 weeks? 1. Assessing response at two weeks likely does not yield clinically meaningful information 2. Symptom improvement at two weeks is highly predictive of overall treatment response 3. No symptom improvement at two weeks is highly predictive of overall treatment failure 4. Assessing for improvement at two weeks is only useful in severely depressed patients Learning Objectives 1. Develop strategies for effectively screening patients for depression within the boundaries of the primary care office visit. 2. Evaluate measurement based care, specifically the APA guidelines, and strategies to address failure of initial antidepressant therapy. 3. Apply clinical data and guideline recommendations in creating an individualized, appropriate, and effective treatment plan The Status Quo Physicians fail to recognize depression in 3 5% of patients Only 5% of patients receive minimally adequate pharmacologic treatment Less than % receive minimally adequate psychotherapy visits Healthy People 22: Mental Health Goals Several Healthy People 22 goals pertain to depression: Increase the proportion of primary care facilities that provide mental health treatment onsite or by paid referral Reduce the proportion of persons who experience major depressive episodes Increase the proportion of adults aged 18 and older with major depressive disorder (MDD) who receive treatment Increase depression screening by primary care providers Simon GE, et al. Gen Hosp Psychiatry. 22;24(4): Healthy People 22. Available at: objectiveslist.aspx?topicid=28. Accessed September
6 Challenging the Traditional Model The DIAMOND Model A plurality of trials have evaluated collaborative care models for depression Two 212 systematic reviews evaluated a total of 69 randomized trials of collaborative care 1,2 Consistently more effective than traditional model Higher response to treatment Higher remission rates Improved treatment adherence Improved quality of life and functional status DIAMOND Depression Intiative Across Minnesota, Offering a New Direction Designed by the Institute for Clinical Systems Improvement (ICSI) Payment redesign targeted to realign incentives DIAMOND model included 8 primary care practices; 7 health plans 1 Thota AB, et al. Am J Prev Med. 212;42(5): ; 2 Jacob V, et al. Am J Prev Med. 212;42(5): Pietruszewski P. Psychiatr Serv. 2;61(): The DIAMOND Model The DIAMOND Model Consists of four processes: Standardized assessment and monitoring (PHQ 9) Registry for tracking patients Stepped care for intensifying and changing treatment Measures to prevent relapse Introduces two new players: Care manager for follow up, coordination Consulting psychiatrist for recommendations Physician Patients 18 years of age with: Diagnosed dysthymia/mdd or PHQ 9 score Case Manager Screened for EtOHism, anxiety, bipolar disorder; Scenario and PMH gathered; Presented to psychiatrist weekly Psychiatrist Reviews weekly for recommendations Results in: no wait times to be seen, more patients seen per week, greater focus of resources, problems addressed in shorter timeframe Pietruszewski P. Psychiatr Serv. 2;61(): Pietruszewski P. Psychiatr Serv. 2;61(): The DIAMOND Model: Outcomes at Six Months Grand Challenges in Global Mental Health: The Burden of Depression % of Patients Achieving Remission Six month Remission 26% 8% 6% Primary Care Behavioral Health Clinics DIAMOND Clinics Care Model Pietruszewski P. Psychiatr Serv. 2;61(): Collins PY, et al. Nature. 211;475(7354):
7 Multidimensionality of Mood Disorders Relative Risk of Cardiovascular and Overall Mortality from the Nurses Health Study Migraine Personality disorders Pain disorders ADHD Diabetes mellitus Mood Disorder Impulse control Cardiovascular Anxiety disorders Obesity Eating disorders Substance abuse The prevalence and epidemiology of psychiatric and medical comorbidities in mood disorders is high Stress sensitive medical disorder prevalent Cardiometabolic disorders most common specific cause of premature mortality Cardiovascular Mortality N=78,282 (aged yrs) Overall Mortality McIntyre RS, et al. Hum Psychopharmacol. 24;19(6): Pan A, et al. Arch Gen Psychiatry. 211;68(1):42 5. Adiposity, Inflammation and Depression Increased Inflammation Predicts Higher HAM D Scores & Treatment Resistance HAM D Correlation of IL 6 and HAM D scores r=.38, P= IL 6 (pg/ml) IL 6 (pg/ml) IL 6 vs. Treatment Response P<.1 P<.1 P<.5 controls responsive refractory IL 6=interleukin 6; HAM D=Hamilton Rating Scale for Depression Shelton RC and Miller AH. Prog Neurobiol. 2;91(4): Yoshimura R, et al. Prog Neuropsychopharmacol Biol Psychiatry. 29;33(4): Body Mass Index: Impact on Antidepressant Response Response to antidepressant treatment according to weight status. Mean Hamilton Depression test (HAM D) rating scores and SEMs for 5 weeks after hospitalization (left) in normal body mass index (BMI) and high BMI patients and (right) in normal BMI, overweight, and obese patients CBT & Inflammation: Symptom, and Neurobiological Marker Improvement Change in IL 6 HAM D score 29 BMI BMI > admission week 1 week 2 week 3 week 4 week 5 HAM D score BMI 25 25< BMI 3 BMI >3 13 admission week 1 week 2 week 3 week 4 week Pg/mL Effect size (UC CBT vs UC)=.61 Change in CRP Effect Effect Size size (UC CBT vs vs UC)= UC)=.85 SEM=specific event memory Kloiber S, et al. Biol Psychiatry. 27;62(4): CRP = C reactive protein; CBT= cognitive behavioral therapy CABG = coronary artery bypass graft Doering LV, et.al. Altern Ther Health Med. 27;13(3):
8 Remission is the Goal Remission is the Goal % Reduction in Score Remission >75% Response 5% 74% Partial Response 25% 49% Nonresponse <25% % Reduction in Score Remission >75% APA MDD Treatment Guidelines: The goal of acute phase treatment Response for major depressive 5% 74% disorder, insofar as possible, Partial is to Response achieve remission 25% and 49% a return to full functioning and quality of life. Nonresponse <25% Remission also defined as attainment of a virtually asymptomatic status (17 item Hamilton Depression Rating Scale [HDRS] score 7) for at least two consecutive weeks. Frank E, et al. Arch Gen Psychiatry. 1991;48(9): ; McIntyre R, et al. J Psychiatry Neurosci. 22;27(4): Remission also defined as attainment of a virtually asymptomatic status (17 item Hamilton Depression Rating Scale [HDRS] score 7) for at least two consecutive weeks. American Psychiatric Association. Practice Guidelines for the Treatment of Patients with Major Depressive Disorder, 3 rd Edition. 2. Definition of Outcomes Response (without remission) 5% decrease in baseline depression scores Remission HAM D score 7 (also referred to as HDRS) QIDS SR score 5 QIDS SR=Quick Inventory of Depression Symptomology Self Report Trivedi MH, et al. Am J Psychiatry. 26;163(1):28 4. IDS C 3 total score Measurement Based Care Leads to Better Outcomes vs. Usual Care Prospective trial evaluating clinical outcomes for patients with MDD (N=35) receiving algorithm guided treatment or treatment as usual Baseline IDS C 3 : 3 item Inventory of Depressive Symptomatology Clinician Rated Scale Months Treatment as usual (N=175) Algorithm guided treatment (N=175) Trivedi MH, et al. Arch Gen Psychiatry. 24;61(7): Causes of Non Remission in Major Depressive Disorder Evidence Based Treatment Options Failure to establish the diagnosis Absence of measurement based care Complex illness presentations Absence of early improvement SSRIs (fluoxetine, paroxetine, etc) SNRIs (duloxetine, venlafaxine) NRIs (bupropion) 5HT 2 antagonists (trazodone) Atypical antipsychotics (aripiprazole, quetiapine, etc) Noradrenergic antagonist (mirtazapine) TCAs (amitriptyline, nortriptyline, etc) MAOIs (phenelzine) 5
9 Other Treatment Options Non Drug Therapy/Procedures Buspirone Folate Inositol Lamotrigine Lithium Melatonin Omega 3 fatty acids Pindolol Psychostimulant (e.g., modafinil) S adenosyl methionine (SAM e) St. John s wort Testosterone Thyroid hormone Acupuncture Deep brain stimulation (DBS) Electroconvulsive Therapy (ECT) Light therapy Psychosurgery Psychotherapy Transcranial Magnetic Stimulation (TMS) Vagus Nerve Stimulation (VNS) Tools to Assess Response & Remission CANMAT Recommendations for Incomplete Response to an Initial Antidepressant Measure Time to complete (mins) Patient/ clinician rated Symptoms 9 item Patient Health Questionnaire (PHQ 9) <3 Patient 17 item Hamilton Depression Rating Scale (HDRS 17) 3 Patient or clinician Beck Depression Inventory (BDI) 5 Patient Montgomery Asberg Depression Rating Scale (MADRS) 15 Patient or clinician Quick Inventory of Depressive Symptomatology Self Report (QIDS SR) 5 Patient or clinician Toronto 7 item Hamilton Depression Rating Scale (HDRS 7) NA Clinician Sheehan Disability Scale (SDS) 1 2 Patient or clinician First line switch Duloxetine Escitalopram Milnacipran* Mirtazapine Sertraline Venlafaxine First line add on Aripiprazole Lithium Olanzapine Risperidone Download: PHQ 9 at primarycare.org and HAM D 7 at McIntyre RS. J Clin Psychiatry. 2;71(Suppl1):16 2. CANMAT=Canadian Network for Mood and Anxiety Treatments *Not FDA approved for treating depression Lam RW, et al. J Affect Disord. 29;117(Suppl 1):S26 S43. Treatment Strategies Options Optimization Augment the treatment regimen with a nonantidepressant agent Combine the initial antidepressant with a second antidepressant Switch to a different antidepressant (within class or across classes) Optimization Adequate adherence 2% of TRD is attributable to nonadherence underestimate 1/3 of patients are nonadherent to antidepressant therapy Adequate dose Adequate duration Papakostas GI. J Clin Psychiatry. 29;7(Suppl 6): TRD=treatment resistant depression Souery D, et al. Eur Neuropsychopharmacol. 1999;9(1 2):83 91; Nemeroff CB. J Clin Psychiatry. 23;64(Suppl 18):
10 Options Optimization Augmentation Combination Switching Treatment Strategies Are We Reassessing Too Late? Early Improvement at 2 Weeks Predicts Response Early improvement at week 2 (N=4284) 53% Went on to have a stable response Stable response No stable response No improvement at week 2 (N=2263) 89% Did NOT go on to have a stable response Lack of improvement in first 2 weeks of treatment may indicate that changes in management should be considered Early Improvement: 2% score reduction from baseline on the HDRS 17 within 2 weeks of treatment Follow up response determined at wk 4 8 Papakostas GI. J Clin Psychiatry. 29;7(Suppl 6): Szegedi A, et al. J Clin Psych. 29;7(3): Case #1: Debbie 35 year old WF Works in call center for major credit card company Medical History: HTN (HCTZ 25 mg QD), seasonal allergic rhinitis Social History: +Tobacco (1/2 ppd), +EtOH (1 2 beers/wk) Family History: Son (ADHD), mother (treated with antidepressants), sister (substance abuse in high school) Psychiatric History: Onset of depressive symptoms at age 25 after husband s affair; now divorced x 6 yrs Previously has taken four antidepressants: Paroxetine (max dose 2 mg; weight gain, sexual adverse effects; duration of tx=4 6 months) Bupropion (max dose 15 mg; headache, agitation) Escitalopram (currently on 2 mg x 3 months; experiencing mild orgasmic delay) Case: Debbie Diagnosis Debbie: MDD Difficult to treat Failed three separate pharmacologic approaches Bipolar disorder ruled out Most difficult symptoms: Insomnia Irritability Case: Approach to Treatment for MDD Make diagnosis Choose reasonable intervention Follow through with intervention Measurement based approach with: Set visit schedule Regular monitoring of symptom improvement, side effects, medication adherence Set dose titration and treatment algorithm Use of critical decision points 7
11 Are We Reassessing Too Late? Early Improvement at 2 Weeks Predicts Response Early improvement at week 2 (N=4284) 53% Went on to have a stable response Stable response No stable response No improvement at week 2 (N=2263) 89% Did NOT go on to have a stable response Lack of improvement in first 2 weeks of treatment may indicate that changes in management should be considered Early Improvement: 2% score reduction from baseline on the HDRS 17 within 2 weeks of treatment Follow up response determined at wk 4 8 Treating Depression in the Real World Remission, not response, is the goal Should first treatment fail, either switching or augmenting is reasonable For most patients, remission requires repeated trials of sustained, vigorously dosed antidepressant medication Likelihood of remission substantially decreases after two adequate treatment trials, suggesting need for more complicated regimens and psychiatric consultation Szegedi A, et al. J Clin Psych. 29;7(3): Gaynes B, et al. Cleve Clin J Med. 28;75(1): Strategies for Refractory Depression STAR*D Treatment Strategies and Options Switch to a different antidepressant (within class or across classes) Augment the treatment regimen with a nonantidepressant agent Combine the initial antidepressant with a second antidepressant Psychosocial Intervention Manual Based Therapy (e.g., Cognitive Behavioral Therapy) Family Focused Therapy (FFT) Psychoeducation/Bibliotherapy Others BUP SR SERT CIT: citalopram CT: cognitive therapy BUS: buspirone BUP SR: bupropion sust. rel. Li: lithium MIRT: mirtazapine NTP: nortriptyline SERT: sertraline T 3:triiodothyronine TCP: tranylcypromine VEN XR: venlafaxine ext. rel. SWITCH VEN XR SWITCH MIRT TCP NTP Citalopram CT BUP SR SWITCH LEVEL 1 CT + CIT SWITCH VEN XR Li + BUP SR, SERT, VEN XR, or CIT MIRT + VEN XR CIT + BUP SR LEVEL 2A AUGMENT AUGMENT T 3 + BUP SR, SERT, VEN XR, or CIT LEVEL 4 CIT + BUS LEVEL 3 LEVEL 2 Papakostas GI. J Clin Psychiatry. 29;7(Suppl 6): Adapted from Warden D, et al. Curr Psychiatry Rep. 27;9(6): STAR*D Cumulative Remission Rates STAR*D Clinical Study Results Remission Rates (HAM D 17 7) Cumulative Remission Rates (%) % 63% 57% 33% Level 1 Level 2 Level 3 Level 4 Gaynes B, et al. Cleve Clin J Med. 28;75(1): Level 2 Level 1 (1 failure) 11.9 weeks 8 weeks 3 Mono Augm 2 Low Mono Level 3 (2 failures) 14 weeks Level 4 (3 failures) 14 weeks Mono = monotherapy Augm = combination treatment McGrath P, et al. Am J Psychiatry. 26; Rush A, et al. Am J Psychiatry. 26; Nierenberg A, et al. Am J Psychiatry. 26; Trivedi M, et al. Am J Psychiatry. 26; Trivedi M, et al. N Engl J Med. 26. Augm Treatment Resistance Mono Augm Mono High 8
12 Remission Rates in STAR*D Level 1 Citalopram STAR*D: Level 2 Medication Switch Citalopram to Bupropion SR, Sertraline, or Venlafaxine XR 5 47% 5 % Patients % 33% HRSD 17 QIDS SR % 26% 18% 27% 25% 25% HRSD 17 QIDS SR 16 Response Remission Bupropion SR Sertaline Venlafaxine XR N=2,876 HRSD 17 response not reported Trivedi MH, et al. Am J Psychiatry. 26;163(1):28 4. N=727 P=Not significant among groups Rush AJ, et al. N Engl J Med. 26;354(12): Non STAR*D evaluated Medication Switch SSRI to Duloxetine STAR*D: Level 2 Switch Cognitive Therapy Versus Medication P.1 vs. baseline 36% 37% Direct Switch Taper Switch Although not included in the STAR*D framework, CANMAT recommendations include duloxetine as a first line switch Study at left included switches from any SSRI to duloxetine Remission measured via changes in HRSD 17 scores HRSD 17 QIDS SR 16 31% 28% 27% 25% Graph at left shows CBT vs. all Level 2 pharmacotherapy strategies (augmentation and switch) Results were similar between both groups Pharmacotherapy groups achieved remission faster, but had a side effect burden Duloxetine CBT Medication Strategies N=168 P=Not significant between groups Perahia DG, et al. J Clin Psych. 28;69(1):95 5. N=122 P=Not significant among groups Thase ME, et al. Am J Psychiatry. 27;164(5): STAR*D: Level 3 Medication Switch Mirtazapine or Nortriptyline STAR*D: Level 4 Medication Switch Tranylcypromine or Mirtazapine Combined With Venlafaxine XR % 8% 2% 12% HRSD 17 QIDS SR % 14% 14% 16% HRSD 17 QIDS SR 16 Mirtazapine Nortiptyline Tranylcypromine Venlafaxine XR + Mirtazapine N=235 P=NS among groups Fava M, et al. Am J Psychiatry. 26;163(7): N=9 P=NS among groups McGrath PJ, et al. Am J Psychiatry. 26;163(9):
13 STAR*D: Level 2 Medication Augmentation Bupropion SR or Buspirone Non STAR*D Evaluated Augmentation Adding Atypical Antipsychotics to SSRIs % 39% 3% 33% HRSD 17 QIDS SR 16 Remission OR: 2. (95% CI )** Discontinuation for Adverse Events OR: 3.91 (95% CI )** NNT = 9 NNH = 17 Remission rate 3.7% vs. 17.2% for placebo Adverse event discontinuation rate 9.1% vs. 2.3% for placebo Augmentation with an atypical antipsychotic is also a first line CANMAT strategy not evaluated in STAR*D Meta analysis at left includes trials of augmenting initial SSRI failure with select* atypicals Remission measured via changes in HDRS 17 scores N=656 P=NS among groups Bupropion SR Buspirone Trivedi MH, et al. N Engl J Med. 26;354(12): *AAs 16 Trials; include 3,48 olanzapine, patients risperidone, quetiapine, aripiprazole **P<.1 Atypical antipsychotic (AA) vs. placebo Nelson JC, Papakostas G. Am J Psychiatry. 29;166(9): STAR*D: Level 3 Medication Augmentation Lithium or Triiodothyronine Summary and Conclusions % 15% Lithium* 25% 23% Triiodothyronine HDRS 17 QIDS SR 16 Depression is under recognized and undertreated in current primary care practice Adequate screening can be performed within the confines of the modern office visit Remission is an achievable treatment goal Early (2 week) follow up may predict response Algorithm guided care improves patient outcomes *Lithium group had significantly higher d/c rates; N=142; P=NS among groups for efficacy Nierenberg AA, et al. Am J Psychiatry. 26;163(9): Which of the following is a realistic goal for a patient undergoing treatment for MDD? Post test 1. 75% reduction in depression score % reduction in depression score % reduction in depression score 4. <25% reduction in depression score
14 Which of the following is not an appropriate firstline switch in a patient who has failed an SSRI? Which of the following can most reliably be performed in the confines of the modern 15 minute office visit? 1. Escitalopram 2. Duloxetine 3. Buspirone 4. Mirtazapine 5. Bupropion 1. 9 item Patient Health Questionnaire item Hamilton Depression Rating Scale 3. Montgomery Asberg Depression Rating Scale 4. Quick Inventory of Depressive Symptomatology Self Report Which of the following statements is true regarding antidepressant response at 2 weeks? 1. Assessing response at two weeks likely does not yield clinically meaningful information 2. Symptom improvement at two weeks is highly predictive of overall treatment response 3. No symptom improvement at two weeks is highly predictive of overall treatment failure 4. Assessing for improvement at two weeks is only useful in severely depressed patients Questions & Answers? 11
Clinical Perspective on Conducting TRD Studies. Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark
Clinical Perspective on Conducting TRD Studies Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark Overview of Presentation Treatment-Resistant Depression (TRD)
More informationAugmentation and Combination Strategies in Antidepressants treatment of Depression
Augmentation and Combination Strategies in Antidepressants treatment of Depression Byung-Joo Ham, M.D. Department of Psychiatry Korea University College of Medicine Background The response rates reported
More informationTreating treatment resistant depression
Treating treatment resistant depression These slides are the intellectual property of Ian Anderson and must not be reproduced Ian Anderson Neuroscience and Psychiatry Unit University of Manchester and
More informationThe scope of the problem. Literature review
Past Year: Novartis Ever: Alkermes, Amylin, Behringer- Ingelheim, Biovail, Bristol-Myers Squibb, Eli Lilly, Embryon, GlaxoSmithKline, Merck, Organon, Park-Davis, Pfizer, Sanolfi-Aventis, Smith-Kline Beacham,
More informationTreatment strategies in major depression What to use when?
Treatment strategies in major depression What to use when? Michael Bauer, MD, PhD Professor and Chair of Psychiatry University Hospital Carl Gustav Carus Technische Universität Dresden Germany First-line
More informationMedication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford
Medication for Anxiety and Depression PJ Cowen Department of Psychiatry, University of Oxford Topics Medication for anxiety disorders Medication for first line depression treatment Medication for resistant
More informationHow to treat depression with medication: Some rules of thumb
How to treat depression with medication: Some rules of thumb R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon. Consultant Psychiatrist Regional
More informationComorbid Conditions and Antipsychotic Use in Patients with Depression
Comorbid Conditions and Antipsychotic Use in Patients with Depression Thomas W. Heinrich, MD Professor of Psychiatry and Family Medicine Director, Division of Consultation-Liaison Psychiatry Medical College
More informationPsychiatry in Primary Care: What is the Role of Pharmacist?
Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure
More informationClinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant
The Clinical Significance of Anxiety Disorders and the DSM-5 Anxious Distress Specifier in Depressed Patients Clinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant Rhode Island
More informationObjectives. Objectives. A practice review. 02-Nov-16 MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS
MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS Jon-Paul Khoo What is treatment resistance really? Database review 328 consecutive non-remitted MDD patients referred for private
More informationMEDICATION ALGORITHM FOR ANXIETY DISORDERS
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON
More informationTreatment Management and the
Evidence-based Sequenced Treatment Management and the 2010 APA Practice Guideline George I. Papakostas, MD Director, Treatment-Resistant Depression Studies Department of Psychiatry Massachusetts General
More informationGraylands Hospital Drug Bulletin
Graylands Hospital Drug Bulletin Antidepressant Combination and Augmentation Strategies North Metropolitan Area Mental Health Service October 2008 Vol 15 No.4 ISSN 1323-1251 Introduction Depression is
More informationIs Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College
More informationCurrent. p SYCHIATRY. Treatment-resistant. Switch or augment? Choices that
Treatment-resistant Switch or augment? Choices that depression improve response rates When initial antidepressant therapy fails, an algorithmic approach to medication is more effective than treatment-as-usual.
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More information3. Depressione unipolare
3. Depressione unipolare Depressione unipolare con mancata risposta al trattamento con SSRI Question: Should switching from SSRIs to another antidepressant class vs switching within class (SSRIs) be used
More informationRecognizing and Responding to Inadequately Treated Major Depressive Disorder (MDD)
Objectives Recognizing and Responding to Inadequately Treated Major Depressive Disorder (MDD) Discuss the burden of MDD on the individual and society Explore the negative impact of residual symptoms Identify
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 6. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationFlorida Best Practice Medication Guidelines Principles of Practice for Adults
http://flmedicaidbh.fmhi.usf.edu Florida Best Practice Medication Guidelines Principles of Practice for Adults 1. Goal of the Guidelines Persistent gaps exist in the quality of mental health care delivered
More informationIs Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College
More informationWhere to from Here? Evidence-Based Strategies for Treatment of Refractory Depression
Where to from Here? Evidence-Based Strategies for Treatment of Refractory Depression Michael D. Jibson, MD, PhD Professor of Psychiatry University of Michigan Major Depression #1 WHO cause of disability
More informationPractice Guideline for the Treatment of Patients With Major Depressive Disorder: American Psychiatric Association
Practice Guideline for the Treatment of Patients With Major Depressive Disorder: American Psychiatric Association Our clinical advisor adds updated advice on electroconvulsive therapy, transcranial magnetic
More informationClinical Guideline for the Management of Bipolar Disorder in Adults
Clinical Guideline for the Management of Bipolar Disorder in Adults Goal: To improve the quality of life of adults with bipolar disorder Identification and Treatment of Bipolar Disorder Criteria for Diagnosis:
More informationFamily Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University
APPROACH TO DEPRESSION IN PRIMARY CARE Family Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University DISCLOSURE Speaker/Presenter Disclosure
More informationPRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA
CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment
More informationRecent Advances in the Treatment of Major Depression
Recent Advances in the Treatment of Major Depression Antidepressant Drugs: Unmet Needs in 2015 Limited efficacy (~ 10-20% advantage vs PBO in RCTs) Intolerable side effects for some Inconsistent effects
More informationThe Pharmacological Management of Bipolar Disorder: An Update
Psychobiology Research Group The Pharmacological Management of Bipolar Disorder: An Update R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon.
More informationReducing the Anxiety of Pediatric Anxiety Part 2: Treatment
Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,
More informationEffective Health Care
Number 7 Effective Health Care Comparative Effectiveness of Second- Generation Antidepressants in the Pharmacologic Treatment of Adult Depression Executive Summary Background Depressive disorders such
More informationTreatment-resistant depression in primary care
Treatment-resistant depression in primary care Interprofessional CME, October 2017 Brian J. Mickey, MD, PhD Associate Professor School of Medicine Department of Psychiatry Disclosures Speakers bureau:
More informationPsychiatry curbside: Answers to a primary care doctor s top mental health questions
Psychiatry curbside: Answers to a primary care doctor s top mental health questions April 27, 2018 Laurel Ralston, DO Psychiatrist, Taussig Cancer Institute Objectives Review current diagnostic and prescribing
More informationSetting ambitious goals for patients with depression with a focus on functional recovery
Setting ambitious goals for patients with depression with a focus on functional recovery The role of the overlooked cognitive symptoms in the treatment of depression Dr Andreas Papadopoulos Locum Consultant
More informationIndex. Bulimia, 13 Bupropion, 12, 51 Buspirone, 81
Index A α-adrenergic blockade, 55 Ablative neurosurgery, 83 Activity scheduling, 61 Acupuncture, 64, 69 71 Alcohol, 7, 13 Alprazolam, 50 Amfebutamone, 52 Amitriptyline, 34 Anhedonia, 13, 17, 18 Anterior
More informationMeasurement-based Scales in Major Depressive Disorder:
This program is paid for by Otsuka Pharmaceutical Development & Commercialization, Inc. and Lundbeck, LLC. The speaker is a paid contractor of Otsuka Pharmaceutical Development and Commercialization, Inc.
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationDepression in Late Life
Depression in Late Life Robert Madan MD FRCPC Geriatric Psychiatrist Key Learnings Robert Madan MD FRCPC Key Learnings By the end of the session, participants will be able to List the symptoms of depression
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 5. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationEffective Date: 5/28/2014 Version: 2.0 (Revised: 10/12/2015) Approval By: CCC Clinical Delivery Steering Planned Review Date: (04/47/2017)
Protocol Title: Depression & Generalized Anxiety Disorder Effective Date: 5/28/2014 Version: 2.0 (Revised: 10/12/2015) Approval By: CCC Clinical Delivery Steering Planned Review Date: (04/47/2017) Group
More informationTreatment Resistant Depression: A Systematic Approach to Management
Treatment Resistant Depression: A Systematic Approach to Management Michael E. Thase, M.D. University of Pennsylvania School of Medicine Philadelphia Veterans Affairs Medical Center University of Pittsburgh
More informationEvidence-Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition
SPECIAL ARTICLE Psychiatry & Psychology http://dx.doi.org/10.3346/jkms.2014.29.4.468 J Korean Med Sci 2014; 29: 468-484 -Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition
More informationers_practice_parameter.pdf
These Guidelines were based in part from on following: Treatment of Patients With Major Depressive Disorder from the American Psychiatric Association (APA) that was amended by the following Guideline Watch
More informationDocument Title Pharmacological Management of Generalised Anxiety Disorder
Document Title Pharmacological Management of Generalised Anxiety Disorder Document Description Document Type Policy Service Application Trust Wide Version 1.1 Policy Reference no. POL 201 Lead Author(s)
More informationTHE ANTIDEPRESSANT PRIMER PETER ROY-BYRNE MD PROFESSOR OF PSYCHIATRY UNIVERSITY OF WASHINGTON
THE ANTIDEPRESSANT PRIMER PETER ROY-BYRNE MD PROFESSOR OF PSYCHIATRY UNIVERSITY OF WASHINGTON OUTLINE Do Antidepressants Work? Are all Antidepressants the Same? Importance of Dose and Treatment Duration
More informationGoals of the talk PSYCHOPHARMACOLOGY FOR DEPRESSION AND MOOD DISORDERS: TIPS FOR SUCCESS. Conflict of Interest: last 12 months. Mark Hyman Rapaport MD
PSYCHOPHARMACOLOGY FOR DEPRESSION AND MOOD DISORDERS: TIPS FOR SUCCESS Mark Hyman Rapaport MD Conflict of Interest: last 12 months Consultant/Advisor: Braincells Inc, AffectisPharma, Cypress, Johnson and
More informationANXIOUS DEPRESSION. Ned H. Kalin, MD University of Wisconsin Alan F. Schatzberg, MD Stanford University
ANXIOUS DEPRESSION Ned H. Kalin, MD University of Wisconsin Alan F. Schatzberg, MD Stanford University NED H. KALIN, MD Disclosures!! Research/Grants: None!! Speakers Bureau: None!! Consultant: None!!
More informationDepression. Affects 6.7% of adult population Women affected twice as much as men Leading cause of disability from all medical illnesses
Advances in Depression Research: A Report From NIMH Mayada Akil, M.D. Senior Advisor to the Director National Institute of Mental Health Depression Affects 6.7% of adult population Women affected twice
More informationDiagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationDrug Surveillance 1.
22 * * 3 1 2 3. 4 Drug Surveillance 1. 6-9 2 3 DSM-IV Anxious depression 4 Drug Surveillance GPRD A. (TCA) (SSRI) (SNRI) 20-77 - SSRI 1999 SNRI 2000 5 56 80 SSRI 1 1999 2005 2 2005 92.4, 2010 1999 3 1
More informationCharles B. Nemeroff, M.D., Ph.D.
CASE STUDY 1 Charles B. Nemeroff, M.D., Ph.D. Leonard M. Miller Professor and Chairman Department of Psychiatry and Behavioral Sciences Director, Center on Aging University of Miami Miller School of Medicine
More informationJune 2015 MRC2.CORP.D.00030
This program is paid for by Otsuka America Pharmaceutical, Inc. and Lundbeck, LLC. The speaker is a paid contractor of Otsuka America Pharmaceutical, Inc. June 2015 MRC2.CORP.D.00030 advice or professional
More informationPresentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More informationResistance is not futile: working with refractory depression and anxiety
Resistance is not futile: working with refractory depression and anxiety Divulgation des conflits d intérêts Conseil consultatif ou comité analogue Essais cliniques ou études Honoraires ou autres revenus
More informationMedications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation
Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral
More informationDepartment of Psychiatry & Behavioral Sciences. University of Texas Medical Branch
Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division
More informationDepression in the Medically Ill
Mayo School of Continuous Professional Development Psychiatry in Medical Settings February 9 th, 2017 Depression in the Medically Ill David Katzelnick, M.D. Professor of Psychiatry, Mayo Clinic College
More informationKey Slides. Progress in Schizophrenia and Bipolar Disorder: Update Numbers of Patients at each Level 3,671 1,
Of Ultimate Responders, 2/3 Responded by Week 6 What Have We Learned From STARD? 3 25 2 Percent 15 1 5 17.8 65.2% 24.5 22.9 N = 2876 Response = 5% QIDS-SR 16 11.5 11. 7.6 4.9 2 4 6 8 1 12 >13 Weeks Trivedi
More information9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationPresenter Disclosure. Objectives 6/5/2017. Depression, Anxiety, PTSD: A Focus on Pharmacotherapy
Depression, Anxiety, PTSD: A Focus on Pharmacotherapy Robert L Page II, Pharm.D., MSPH, FHFSA, FCCP, FAHA Professor of Clinical Pharmacy Clinical Specialist, Division of Cardiology University of Colorado
More informationPharmacy Prior Authorization GMH/SA and Non-Title 19/21 SMI Non-Formulary and Prior Authorization Guidelines
Non-Formulary Behavioral Health Medications ADHD medications for children under The patient must have a diagnosis for which the requested medication is: o Approved based on FDA indication and limits; OR
More informationApproaches to Treatment Resistant Depression (TRD): An Update Focusing on Studies Published in
An Update Focusing on Studies Published in 2011-2013 Albert Yeung, M.D., ScD Associate Professor of Psychiatry Harvard Medical School This is a summary of a review of approaches to treatment resistant
More informationTREATING MAJOR DEPRESSIVE DISORDER
TREATING MAJOR DEPRESSIVE DISORDER A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Second Edition, originally published in April 2000.
More informationCharles B. Nemeroff, M.D., Ph.D.
CASE STUDY 2 Charles B. Nemeroff, M.D., Ph.D. Leonard M. Miller Professor and Chairman Department of Psychiatry and Behavioral Sciences Director, Center on Aging University of Miami Miller School of Medicine
More informationDisclosures. Overview of Workshop. Objectives. Medical Care of Vulnerable and Underserved Populations: Advanced Cases in Anxiety and Depression
Medical Care of Vulnerable and Underserved Populations: Advanced Cases in Anxiety and Depression Disclosures The speakers have no disclosures. Lisa Ochoa-Frongia, MD Christina Mangurian, MD, MAS L. Elizabeth
More informationIndex. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers
Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic
More informationANXIETY: FAST FACTS AND SKILLS FOR THE PRIMARY CARE PHYSICIAN
UW PACC Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences ANXIETY: FAST FACTS AND SKILLS FOR THE PRIMARY CARE PHYSICIAN RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL
More informationObjectives. Sexual dysfunction (SD) SD in the general population. Assessment of sexual functioning ANTIDEPRESSANT-INDUCED SEXUAL DYSFUNCTION
Objectives To appreciate the relationship between major depressive disorder, its treatment and sexual dysfunction To review the assessment of sexual function An approach to the clinical management of antidepressant
More informationPsychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI
Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT
More informationDisclosure Information
Disclosure Information I have no financial relationships to disclose. I will discuss the off label use of several depression and anxiety medications in pediatric population Pediatric Depression & Anxiety
More informationDaniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School
Daniel Suzuki, MD Adjunct Clinical Associate Professor of Psychiatry, USC Keck School of Medicine Clinical Adjunct Professor/Faculty, Graduate School of Psychology, Fuller Theological Seminary Medical
More informationEARLY OPTIMIZED TREATMENT IN DEPRESSION
EARLY OPTIMIZED TREATMENT IN DEPRESSION A Recipe for Successful Recovery Mar. 28, 2017 Jeffrey Habert MD CCFP FCFP Assistant Professor, University of Toronto, Dept. of Family and Community Medicine Investigating
More informationAdult Depression - Clinical Practice Guideline
1 Adult Depression - Clinical Practice Guideline 05/2018 Diagnosis and Screening Diagnostic criteria o Please refer to Attachment A Screening o The United States Preventative Services Task Force (USPSTF)
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize
More information48 th Annual Meeting. Clinical Pearls: Depression, Insomnia and Bipolar Disorder DSM-5. Disclosure. Depression. Patient Case. Objectives 7/19/2014
48 th Annual Meeting Clinical Pearls: Depression, Insomnia and Bipolar Disorder DSM-5 Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Published in 2013 Most published treatment guidelines
More informationBipolar Depression: Engaging the Patient. Mark Frye, MD Mayo Clinic Rochester, MN
Bipolar Depression: Engaging the Patient Mark Frye, MD Mayo Clinic Rochester, MN Mark Frye, MD Disclosures Research/Grants: AssureRX Health Inc.; Janssen Research & Development, LLC; Mayo Foundation for
More informationPSYCHOPHARMACOLOGY BULLETIN: Vol. 42 No. 2 5
DEMITRACK_MWM_549.QXP 7/14/9 1:46 PM Page 5 ORIGINAL RESEARCH Key Words: major depression, treatment resistance, transcranial magnetic stimulation, TMS, antidepressant, efficacy, safety, randomized clinical
More informationNon-A, non-b=hcv; IFN/RBV; DSM-5/Ham-D, OLT; SSRI, P450
James A. Bourgeois, O.D., M.D. Vice Chair Clinical Affairs and Director, CL Service University of California San Francisco Non-A, non-b=hcv; IFN/RBV; DSM-5/Ham-D, OLT; SSRI, P450 Localize! Sequence! 1
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More information#CHAIR2016. September 16 17, 2016 The Biltmore Hotel Miami, FL. Sponsored by
#CHAIR2016 September 16 17, 2016 The Biltmore Hotel Miami, FL Sponsored by Depression in Children and Adolescents Karen Dineen Wagner, MD, PhD University of Texas Medical Branch Galveston, TX Karen Dineen
More informationA Basic Approach to Mood and Anxiety Disorders in the Elderly
A Basic Approach to Mood and Anxiety Disorders in the Elderly November 1 2013 Sarah Colman MD FRCPC Clinical Fellow, Geriatric Psychiatry Mount Sinai Hospital, University of Toronto Disclosure No conflict
More informationDepression: Identification, Evaluation and Management in Primary Care
Depression: Identification, Evaluation and Management in Primary Care Primary Care Medicine: Update 2010 Rena K. Fox, M.D. Associate Professor of Clinical Medicine University of California, San Francisco
More informationDepression in adults: treatment and management
1 2 3 4 Depression in adults: treatment and management 5 6 7 8 Appendix V3: recommendations that have been deleted of changed from 2009 guideline Depression in adults: Appendix V3 1 of 22 1 Recommendations
More informationAntidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry
Antidepressant Medication Strategies We ve Come a Long Way or Have We? Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free
More informationManaging inadequate antidepressant response in depressive illness
British Medical Bulletin, 2015, 115:183 201 doi: 10.1093/bmb/ldv034 Advance Access Publication Date: 26 August 2015 Managing inadequate antidepressant response in depressive illness Peter M. Haddad,, *,
More informationMedication management of anxiety & depression. Dr Katie Simpson GP Mental health lead East Berks CCG
Medication management of anxiety & depression Dr Katie impson GP Mental health lead East Berks CCG NICE guidelines for Anxiety tepped Care RIs and NRIs in Anxiety disorders RI ertraline Citalopram Fluoxetine
More informationKEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.
KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised
More informationAntidepressant Therapy 2016
Antidepressant Therapy 2016 Michael E. Thase, MD University of Pennsylvania School of Medicine Philadelphia Veterans Affairs Medical Center University of Pittsburgh Medical Center thase@mail.med.upenn.edu
More informationBipolar Disorder in Youth
Bipolar Disorder in Youth Janet Wozniak, M.D. Associate Professor of Psychiatry Director, Pediatric Bipolar Disorder Research Program Harvard Medical School Massachusetts General Hospital Pediatric-Onset
More informationUpdate on neurochemistry: Decision-making for Clinicians
Update on neurochemistry: Decision-making for Clinicians Pierre Blier, MD, Ph.D Professor, Psychiatry and Cellular & Molecular Medicine University of Ottawa Endowed Chair and Director Mood Disorders Research
More informationLearning Objectives. Faculty. Why Treat Depression in Primary Care. A Real Case. Presenter Disclosure Information
2:15 3:30 pm Major Depressive Disorder: Improving Models for Care in the Primary Care Setting Presenter Disclosure Information The following relationships exist related to this presentation: Thomas Heinrich,
More informationDepression often comorbid with alcohol dependence 1.6x higher rate of alcohol dependence in depressed subjects Depressed subjects with alcohol
Lindsay French PGY3 Depression often comorbid with alcohol dependence 1.6x higher rate of alcohol dependence in depressed subjects Depressed subjects with alcohol dependence have complicated course of
More informationBipolar Disorder Clinical Practice Guideline Summary for Primary Care
Bipolar Disorder Clinical Practice Guideline Summary for Primary Care DIAGNOSIS AND CLINICAL ASSESSMENT Bipolar Disorder is categorized by extreme mood cycling; manifested by periods of euphoria, grandiosity,
More informationManagement of. Depression: Some observations
Management of Psychobiology Research Group Depression: Some observations Hamish McAllister-Williams Reader in Clinical Psychopharmacology, Newcastle University Hon. Consultant Psychiatrist, Regional Affective
More informationDr.Rahiminejad Roozbeh Hospital TUMS
Dr.Rahiminejad Roozbeh Hospital TUMS Psychiatric disorders, particularly depression, anxiety and eating disorders, are prevalent in diabetes. Mental illness increases risk of diabetes and diabetic complications.
More informationOutline. Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly. Definitions
Outline Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly Michael E. Thase, MD Professor of Psychiatry Perelman School of Medicine University of Pennsylvania and Philadelphia
More information4/29/2016. Psychosis A final common pathway. Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue
Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue Disclosures Financial relationships with commercial interests Douglas R. Robbins, M.D. Maine Medical Center Tufts University
More informationMr. E, age 37, has a 20-year history
Antipsychotics for obsessive-compulsive disorder: Weighing risks vs benefits Taylor Modesitt, PharmD, Traci Turner, PharmD, BCPP, Lindsay Honaker, DO, Todd Jamrose, DO, Elizabeth Cunningham, DO, and Christopher
More informationManual of Clinical Psychopharmacology
Manual of Clinical Psychopharmacology Fourth Edition Alan F. Schatzberg, M.D. Kenneth T. Norris, Jr., Professor and Chairman, Department of Psychiatry and Behavioral Sciences, Stanford University School
More information